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Chiral probes for a1-AGP reporting by species-
speciﬁc induced circularly polarised luminescence†
Sergey Shuvaev,*a Elizaveta A. Suturina, b Kevin Mason a and David Parker *a
Luminescence spectroscopy has been used to monitor the selective and reversible binding of pH sensitive,
macrocyclic lanthanide complexes, [LnL1], to the serum protein a1-AGP, whose concentration can vary
signiﬁcantly in response to inﬂammatory processes. On binding a1-AGP, a very strong induced circularly-
polarised europium luminescence signal was observed that was of opposite sign for human and bovine
variants of a1-AGP – reﬂecting the diﬀerences in the chiral environment of their drug-binding pockets. A
mixture of [EuL1] and [TbL1] complexes allowed the ratiometric monitoring of a1-AGP levels in serum.
Moreover, competitive displacement of [EuL1] from the protein by certain prescription drugs could be
monitored, allowing the determination of drug binding constants. Reversible binding of the
sulphonamide arm as a function of pH, led to a change of the coordination environment around the
lanthanide ion, from twisted square antiprism (TSAP) to a square antiprismatic geometry (SAP), signalled
by emission spectral changes and veriﬁed by detailed computations and the ﬁtting of NMR
pseudocontact shift data in the sulphonamide bound TSAP structure for the Dy and Eu examples. Such
analyses allowed a full deﬁnition of the magnetic susceptibility tensor for [DyL1].
Introduction
The acute phase proteins found in human serum play a multi-
tude of roles in vivo. Deviations from their normal concentration
values can indicate the onset or presence of certain diseases. The
second most abundant protein is a1-acid glycoprotein, a1-AGP,
and uctuations in its serum concentration merit close atten-
tion.1,2 Indeed, it has been hailed as the most important of four
key circulating biomarkers that can be used to assess the ve-
year risk of mortality by any cause.3 It has been shown that a1-
AGP transports a wide range of basic drugs in human plasma,
e.g. methadone, disopyramide and many common anaesthetics
such as lidocaine and bupivacaine, oen competing with the
more abundant serum albumin in this regard.4–6 Up to a 4-fold
increase in its concentration is observed as a consequence of
diﬀerent inammatory processes, including severe chronic
diseases, such as cancer and HIV.7 This signicant change of the
concentration in response to external stimulus, characteristic for
the acute phase proteins, inevitably aﬀects drugmetabolism and
bioavailability, necessitating revised drug prescription for
patients with inammation.8,9
However, there are a very limited number of publications on
a1-AGP selective probes, with even fewer reporting their
performance in serum. In the present paper, we report a series
of new pH-responsive lanthanide complexes [LnL1] (Ln ¼ Y, Eu,
Tb, Dy; Fig. 1), which show a pronounced and species-
dependent aﬃnity towards a1-AGP, and a remarkable varia-
tion in metal complex helicity in the protein bound form, that is
a function of AGP type and of local pH. The conjugated chro-
mophore has a strong ICT transition that imparts sensitivity to
changes in its local environment. Earlier, we reported a euro-
pium DO2A-based probe, [EuL2], bearing two azaxanthone
chromophores that showed selective binding for both a1-AGP
and a1-antitrypsin (a1-AAT) with respect to human serum
albumin (Fig. 2).10–12 It showed an increase of the total emission
intensity and a large induced circularly polarised luminescence
(CPL) upon binding these proteins only. It was hypothesised
that the europium complex was embedded within the drug-
binding pocket, and was bound to the carboxylate oxygen
atom of a Glu-64 residue of a1-AGP, following dissociation of
one of the azaxanthone nitrogen atoms. Juxtaposition of the
amino-acid sequences in a1-AGP for diﬀerent mammalian
Fig. 1 Molecular structure of [LnL1], Ln ¼ Y, Eu, Tb and Dy.
aDepartment of Chemistry, Durham University, South Road, Durham, DH1 3LE, UK.
E-mail: david.parker@dur.ac.uk
bSchool of Chemistry, The University of Southampton, Higheld, Southampton SO17
1BJ, UK
† Electronic supplementary information (ESI) available. See DOI:
10.1039/c8sc00482j
Cite this: Chem. Sci., 2018, 9, 2996
Received 30th January 2018
Accepted 18th February 2018
DOI: 10.1039/c8sc00482j
rsc.li/chemical-science
2996 | Chem. Sci., 2018, 9, 2996–3003 This journal is © The Royal Society of Chemistry 2018
Chemical
Science
EDGE ARTICLE
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
9 
Fe
br
ua
ry
 2
01
8.
 D
ow
nl
oa
de
d 
on
 2
8/
03
/2
01
8 
14
:1
5:
43
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
View Journal  | View Issue
species reveals considerable discrepancies in the residues
lining the drug-binding pocket, suggesting variable drug-
binding aﬃnities for diﬀerent species. However, systematic
analysis of the impact of these deviations on drug binding
aﬃnity is limited.
Results and discussion
Synthetic procedures
The complexes [LnL1] (Ln ¼ Y, Eu, Tb, Dy) were synthesised by
successive alkylation reactions of a DO2A-ethyl ester precursor
(Scheme S1†). The chromophore was synthesised via a Suzuki–
Miyaura cross-coupling reaction in a microwave reactor, using
a Pd(TTP)2Cl2 catalyst. The freshly prepared benzylic meth-
anesulphonate derivative of this chromophore was reacted with
DO2A-ethyl ester, followed by reverse-phase HPLC purication.
The isolated tri-substituted cyclen derivative was subsequently
reacted with N-methanesulfonyl-aziridine, and RP-HPLC puri-
cation yielded the diethyl ester of ligand L1. The ester was
hydrolysed in aq. NaOH solution, neutralised with acid and
reacted with the corresponding LnCl3 salt. The desired [LnL
1]
complexes were puried by reverse-phase HPLC.
Human a1-AGP binding studies of [EuL
1] and [TbL1]
The complexes [TbL1] and [DyL1] each showed a characteristic
ion-centred emission signature, whilst [EuL1] showed very low
emission intensity. As signicant residual ligand uorescence
was not observed, the quenching of emission in [EuL1] is likely
to be due to competitive depopulation of the ligand singlet
excited state by formation of a ligand-to-metal charge transfer
state. Bubbling argon gas through the aqueous solution of
[EuL1] altered neither the magnitude nor the lifetime of the
observed emission, consistent with the singlet nature of the
hypothesised ICT state. By decreasing the polarity of the
solvent, the total emission intensity was signicantly enhanced,
with some changes in the Eu emission spectral signature
observed in less polar solvents, such as THF and 1,4-dioxane
(Fig. S1†). Emission intensity variations did not correlate with
changes in solvent viscosity. The measured lifetime of the
excited state also did not vary, negating the involvement of
a twisted intramolecular charge transfer (TICT) state in the
emission quenching process.
A similar solvent-dependent behaviour was observed in
recent work, where the ICT state in the related europium
complex, [EuL3]13 (Fig. 2), demonstrated a strong solvent
dependence of emission. Indeed, a near exponential increase of
the total emission intensity was found as a function of Reich-
ardt's solvent polarity parameter.13 Furthermore, it was revealed
that addition of HSA resulted in a 100-fold amplication of the
signal intensity, attributed to the signicant polarity change in
the drug-binding pocket.
With this behaviour in mind, similar protein binding studies
were carried out for [EuL1], examining human and bovine
serum albumins, g-ImG, brinogen, a1-AGP (bovine and
human forms) and a1-AAT. Only addition of a1-AGP (human
and bovine) revealed a substantial increase in the total euro-
pium emission intensity, with apparent binding constants
log K¼ 4.1 and 4.7 estimated for the human and bovine species
respectively (Fig. 3). Only for the bovine species was a signicant
change in the spectral signature observed (0.1 M HEPES, pH ¼
7.40).
With added human a1-AGP, [EuL
1] showed an induced CPL
signal that was almost identical to that observed for [EuL3] with
added HSA. A closer inspection of the structure of [EuL1] reveals
a coordination environment almost identical to [EuL3], with two
carboxylate oxygen atoms, a sulphonamide nitrogen atom and
a pyridine nitrogen atom bound to the Eu3+ ion. As less signif-
icant change of the spectral signature was observed upon
addition of human a1-AGP, perturbation of the primary coor-
dination environment is unlikely to have occurred and the
observed induced CPL can be attributed to the preferential
stabilisation of one of the two complex enantiomers, L(llll)
and D(dddd), which exist in equilibrium in aqueous solution. To
assign the observed CPL signature to one of these enantiomers,
a comparison of the CPL spectrum with previously reported
spectra of chiral europium complexes was carried out.14 Such an
analysis resulted in a tentative D (dddd) assignment, (Fig. S9†).
The sulphonamide arm binding behaviour determines the
pH changes in the emission spectrum.15–18 Reversible binding of
the nitrogen to Eu3+ ion occurs in solution with protonation
leading to addition of coordinated water molecules (Scheme 1,
and vide infra). Addition of certain anions and proteins can
signicantly alter the position of the equilibrium, aﬀecting the
pKa associated with protonation of the sulphonamide nitrogen,
Fig. 2 Molecular structures of the bis-azaxanthone complex, [EuL2]12
(left) and of [EuL3]13 (right).
Fig. 3 Change of the total emission intensity upon addition of human
a1-AGP to [EuL
1]; ([EuL1] 9 mM; log K ¼ 4.1(01), assuming a 1 : 1 binding
isotherm, lex ¼ 310 nm, 298 K, pH ¼ 7.40).
This journal is © The Royal Society of Chemistry 2018 Chem. Sci., 2018, 9, 2996–3003 | 2997
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as a result of competitive binding.15 As only a very low emission
intensity was observed for [EuL1] without any added a1-AGP, the
terbium analogue [TbL1] was also used to investigate the
protonation behaviour of the complex.
Only minor changes to the terbium emission pattern were
observed upon lowering the pH from 8.0 to 3.0, whilst the total
emission intensity decreased, consistent with a replacement of
the sulphonamide nitrogen atom by two water molecules. At the
same time, the lifetime of the terbium 5D4 excited state
decreased from 1.85 ms to 1.14 ms, in line with the more eﬃ-
cient non-radiative quenching via energy transfer to the proxi-
mate OH oscillators associated with the coordinated waters.
The apparent pKa of the free Tb complex (4.2(0.1)) was similar
to that measured for [EuL1] when bound to human a1-AGP
(4.6(0.1)).
Protein addition for [TbL1] and [EuL1] increased the lifetime
of the excited state, consistent with the absence of water
molecules bound to the lanthanide ion at both lower and
ambient pH (q ¼ 0). At lower pH, q is also zero; such behaviour
suggests that the bound water was replaced with a carboxylate
oxygen (e.g. the side chain carboxylate oxygen of Glu-64/65 for
human and potentially bovine AGP, respectively) in the protein
bound form of the complex (Table 1).
With the human a1-AGP bound [EuL
1] complex, a concomi-
tant change of the spectral signature with pH was observed. The
most remarkable change occurred in the 5D0/
7F1 transition
(Fig. 4), where a change in the sign of the crystal eld parameter
B20 was observed, by analysing the nature of the DJ ¼ 1 mani-
fold.19,20 The values of B20 and B
2
2 (i.e. dened in terms of
spherical tensor analysis),21b were 556 and 117 cm1 for the
high pH form, and +448 and +92 cm1 in the protein bound
state.
These ndings can be explained in terms of the transition
between the TSAP (with the sulphonamide nitrogen bound at
higher pH) and SAP (with a dissociated sulphonamide nitrogen)
coordination geometries. Attempts to trace these changes by
following chemical shis in the 1H NMR spectrum as a function
of pH were not successful, as very broad signals were observed
at lower pH values, probably as a result of the fast exchange
between conformational isomers in the SAP conguration.
NMR analysis of complex structure
The simulation of NMR pseudocontact shi data (PCS) is
a valuable tool to evaluate the quality of the proposed molecular
structure of a lanthanide complex in solution, by comparing
calculated values with experimentally observed shis. It has
been previously shown that predicted PCS values based on an
optimised X-ray structure of the complex were in a good
agreement with experimentally observed ones.21 As no crystal
structure was available for [LnL1], DFT calculations were
employed instead, and the nal structures are shown above
(Fig. 5). Lifetime measurements had shown that reversible
protonation of the sulphonamide nitrogen at lower pH replaced
it with two water molecules directly bound to the lanthanide
ion, increasing its coordination number from 8 to 9. The
concomitant changes of the sign of B20 term, as evident from the
emission spectrum of Eu (Fig. 4), suggested the change of
coordination environment between TSAP and SAP congura-
tions. To verify this assumption, DFT simulations of structures
of the 8-coordinate TSAP and 9-coordinate SAP isomers (Fig. 5),
augmented by pseudo-contact shi tting of [EuL1] and [DyL1]
were carried out. In addition, 1H NMR and 1H–1H COSY spectra
for the TSAP isomer were measured, (Fig. S2 and S5†).
The 1H NMR spectrum (Fig. S2†), 1H–1H NOESY (Fig. S3†)
and 1H–1H ROESY (Fig. S4†) spectra of [YL1] were used to esti-
mate the diamagnetic contribution to the chemical shis. A
simulated structure of the TSAP isomer for [DyL1] in particular
produced a very good t (Fig. 6 and 7, Tables 2 and S1–S4†).
Scheme 1 Equilibria present in the [LnL1]/a1-AGP system, showing the
protonated and non-protonated forms.
Table 1 Lifetimes of the 5D0 excited state (in H2O and D2O) and
hydration numbers (q) for [EuL1] in the presence of human and bovine
a1-AGP, as well as for [TbL
1] with no added protein
H2O/ms D2O/ms q
Human a1-AGP 0.78 (pH 7.0) 1.04 (pD 7.4) 0.1
0.91 (pH 3.0) 1.17 (pD 3.4) 0
Bovine a1-AGP 0.22 (pH 9.8) 0.22 (pD 10.4) 0
b
0.82 (pH 6.0) 1.33 (pD 6.4) 0.3
No proteina 1.80 (pH 7.0) 1.98 (pD 7.4) 0
1.14 (pH 3.0) 1.92 (pD 3.4) 1.5
a Obtained for [TbL1]; Tb emission lifetimes with added human AGP
were 2.06 (pH 4.1) and 1.63 ms (pH 8.1), and 1.78 ms with added
bovine AGP (pH 6.5), consistent with q ¼ 0 in each case. b At high pH/
pD quenching by charge transfer inhibits the use of the normal
method of lifetime analysis to assess q values, for which the dominant
quenching mechanism must only involve vibrational energy transfer
to OH oscillators.
Fig. 4 Changes of the emission spectrum of [EuL1] in the presence of
human a1-AGP at pH¼ 3.0 (SAP, black) and pH¼ 6.0 (TSAP, red) ([EuL1]
8 mM, a1-AGP 25 mM, lex ¼ 310 nm, 298 K).
2998 | Chem. Sci., 2018, 9, 2996–3003 This journal is © The Royal Society of Chemistry 2018
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Since exchange broadened signals were obtained at lower pH
values for the SAP structure, no tting of its simulated structure
was possible as no PCS values were recorded for the SAP isomer.
The best-t magnetic susceptibility tensor (Table 2) and the
resulting PCS eld (Fig. 6) are very similar in size and orienta-
tion to those found with [DyL4],21a,b consistent with their very
similar TSAP coordination geometries (Fig. 5).
In Bleaney's theory of magnetic anisotropy,21c,d ligand eld
parameters can be computed from the axiality and rhombicity
of the magnetic susceptibility, at the high temperature limit.
B02 ¼ 20
ðkTÞ2
m0mB
2CJ
cax; B2
2 ¼ 10
ﬃﬃﬃ
6
p ðkTÞ2
m0mB
2CJ
crh (1)
According to eqn (1), the ligand eld parameters B20 and
B22 are estimated to be 486 and 137 cm1, which is in quite
good agreement with the parameters extracted from the euro-
pium emission spectra. The small variation might be due to the
diﬀerences in the radial wavefunction between Eu(III) and Dy(III)
or because of the high temperature limit approximation.
The lifetime data had shown that there were no bound water
molecules in the presence of added protein (Table 1). However,
the positive sign of the B20 term was evident analysing the
europium emission spectrum of the protein bound form,
consistent with a very diﬀerent coordination type that is adop-
ted when chelating, for example, the carboxylate oxygens of
a proximate Glu or Asp side chain.
Tables of experimental and calculated shis are given in the
ESI,† together with optimized structural coordinates for the Y,
Eu, Tb and Dy complexes of L1 in the TSAP form and the 9-
coordinate SAP structure with the unbound sulphonamide N
atom and two added waters for Y and Eu. The Y, Eu, Tb and Dy
complexes of L1 are isostructural.
Bovine a1-AGP binding studies of [EuL
1] and [TbL1]
Very diﬀerent emission behaviour was observed in the presence
of bovine a1-AGP, where a change of the spectral signature was
observed upon binding the protein to [EuL1] (0.1 M HEPES, pH
¼ 7.40). At this pH, the resulting emission spectral form
Fig. 5 Optimised structures of [YL1] in octadentate twisted square
antiprismatic (TSAP) coordination geometry and [HYL1(H2O)2]
+ in 9-
coordinate mono-capped square-antiprismatic coordination (SAP).
Fig. 6 Pseudocontact shift ﬁelds for the [DyL1] complex, recon-
structed by Spinach using the best-ﬁt magnetic susceptibility tensor.
Positive PCS is shown in red, negative – in blue, transparency indicates
the absolute value.
Fig. 7 Experimental 1H NMR spectrum of [DyL1] (magenta) and
a simulated spectrum (blue); (1T, 300 K, D2O) showing the comparison
of theoretical and experimental pseudocontact shift values (PCS)
(Tables S1 and S3†).
Table 2 Magnetic susceptibility tensors (SI units) for the complex
[DyL1] in comparison to the related TSAP triphosphinate-mono-pyridyl
complex [DyL4],21 obtained by paramagnetic shift ﬁtting and computed
by CASSCF (in parentheses), expressed in terms of axiality (cax),
rhombicity (crh) and Euler angles
Complex cax/A
3 crh/cax a/ b/ g/
[DyL1] 0.55 0.23 185 20 207
[DyL4] 0.57, (0.59) 0.30, (0.25) 189, (198) 20, (24) 201, (14)
This journal is © The Royal Society of Chemistry 2018 Chem. Sci., 2018, 9, 2996–3003 | 2999
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resembled that observed for [EuL1] with added human a1-AGP,
when the sulphonamide nitrogen was dissociated and replaced
with carboxylate oxygen atoms of the side chain amino-acid.
This behaviour initially suggested a higher pKa value for
[EuL1] with added bovine a1-AGP (Fig. S6–S8†). Indeed, an
apparent pKa of 8.4(0.1) was calculated (Fig. 8). This value is
much higher than that observed for [TbL1] with no added
protein (4.2(0.1)), (Fig. S13†).
Both the total emission intensity and the lifetime of the
excited state experienced a signicant reduction, with the latter
decreasing from s ¼ 0.84 ms (pH 6.2), to s ¼ 0.22 ms (pH 9.9).
The observed strong quenching of emission at higher pH, along
with the elevated pKa value with added bovine (but not human)
a1-AGP suggests a diﬀerent interaction between [EuL
1] and the
amino-acids in the bovine drug-binding pocket.
The absence of a crystal structure of bovine a1-AGP makes it
diﬃcult to be sure about which amino-acids are close in space
to the drug-binding pocket. However, a simulated computer
model of the bovine a1-AGP tertiary structure22a suggests
a signicant correspondence in the structures of human and
bovine variants of the protein, (Fig. S14†), and therefore amino-
acid residues that may be close to the bound drug are expected
to have rather similar positions in the 3D structure. On exam-
ining those residues that are close to the expected drug-binding
site, the aromatic amino-acid Tyr-84 was pinpointed in bovine
a1-AGP; in the human form the nearest Tyr residue is Tyr-78.
The side chain phenol can potentially bind to a sulphonamide
oxygen, through formation of a stabilising hydrogen bond.
When this phenol is deprotonated, i.e. at higher pH, the sul-
phonamide arm can no longer interact with Tyr-84, as the sul-
phonamide nitrogen atom is coordinated to Eu3+ (Fig. 9). At the
same time, the electron rich phenolate of Tyr-84 can quench
[EuL1] emission by a charge transfer mechanism that also
occurred, but to a lesser degree with [TbL1]. It is therefore
plausible that it is the protonation of Tyr-84 that is being
observed in the pH dependence of Eu emission (Fig. 8). The
lowered phenol pKa from its normal value around 9.7, can be
attributed to either an electrostatic eld eﬀect, causing stabili-
sation of the conjugate base by proximate cationic side chains
(e.g. Lys-82, Arg-85), or by a stabilising H-bonding interaction
with a proximate H-bond donor.22b In the human form of AGP,
the nearest Tyr (Tyr-78) in contrast is anked by threonine,
glutamine and leucine residues so no such eld eﬀect seems
possible. Previous examples of the quenching of sensitised Eu
emission by electron rich species, have included urate, ascor-
bate and various catecholates.23
The analysis of the induced CPL spectrum of [EuL1] with
added bovine a1-AGP at higher pH revealed a spectrum of
opposite sign to that observed for [EuL1] with added human a1-
AGP, under the same conditions (Fig. 10 and S9†). This
surprising observation suggests the stabilisation of the complex
with opposite helicity (i.e. the L(llll) enantiomer) for [EuL1]
when it is located within the drug-binding pocket of bovine a1-
AGP. Upon lowering the pH of the solution, the CPL spectrum
also changed, and resembled the inverted signature of [EuL1]
with added human a1-AGP, although not completely matching
it. These small diﬀerences in the CPL and total emission
signatures may be caused by diﬀerences between the amino-
acid moieties, (e.g. a Glu or Asp side chain O) which bind to
Fig. 8 The pH dependence of europium emission in bovine a1-AGP
bound complex [EuL1] (295 K, 0.1 M NaCl, 5 mM [EuL1], 25 mM a1-AGP).
Fig. 9 Rationalisation of the enhanced pKa observed for [LnL
1] when
bound to bovine a1-AGP. In the sulphonamide bound complex, the
proximate phenolate quenches the luminescence by electron transfer.
Fig. 10 Induced CPL spectra of [EuL1] bound with human and bovine
a1-AGP, when the sulfonamide arm is coordinated (pH ¼ 9.3, top) and
when it is not bound (pH ¼ 3.6, lower) to the Eu3+ ion (lex ¼ 310 nm,
D2O, 295 K).
3000 | Chem. Sci., 2018, 9, 2996–3003 This journal is © The Royal Society of Chemistry 2018
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[EuL1] at lower pH values, when the sulphonamide arm is
dissociated.
Similar behaviour was observed for [TbL1] with added
human and bovine a1-AGP (Fig. S10†), when opposite, but not
identical CPL spectral signatures were found for the unbound
sulphonamide. At elevated pH, when the sulphonamide N atom
is coordinated, very weak induced CPL signals were observed for
each protein. Because [TbL1] was emissive in the absence of
protein, and since addition of bovine a1-AGP induced a strong
CPL signal, the change in the dissymmetry ratio, gem, could be
monitored as a function of added protein concentration
(Fig. S11†). Analysis of the resultant binding isotherm revealed
an aﬃnity constant log K ¼ 5.1, which is a somewhat higher
value than that calculated by following the total emission
intensity variation of [EuL1] (log K ¼ 4.7).
Ratiometric monitoring of a1-AGP levels in serum
The a1-AGP concentration in plasma can experience up to
a four-fold increase from normal values, in response to
inammatory stimulus. Accordingly, to foetal calf or human
serum samples was added a mixture of [EuL1] and [TbL1] (22
mM/2 mM) and the variation of the emission intensity ratio was
monitored upon incremental addition of bovine and human a1-
AGP, respectively (Fig. 11 and S21†). In each case, a quasi-linear
dependence between the relative intensities of the Tb 5D4/
7F5
band in [TbL1] and the 5D0/
7F2 transition in [EuL
1] with the
concentration of a1-AGP was observed. A lower apparent
binding aﬃnity was noted, compared to those measured in salt
and buﬀer solution only. This discrepancy might be explained
by competitive binding of [EuL1] and [TbL1] to serum albumin,
decreasing the eﬀective concentration of a1-AGP.
Even though preliminary studies revealed no ‘switch-on’
response for [EuL1] upon addition of human and bovine serum
albumin, a more detailed analysis of its eﬀect on the total
emission intensity of [TbL1] was carried out. In each case, (HSA
and BSA), quenching of the total emission intensity was
observed when excess of the protein was added, with no visible
change of the spectral signature detected. Similar binding
constants were observed with added HSA and BSA (log K ¼ 3.4
and log K ¼ 3.2, respectively, Fig. S22 and S23†), which are two
orders of magnitude lower than the corresponding binding
constants for this complex with a1-AGP. Notwithstanding this
diﬀerence in binding constants, the occurrence of a signi-
cantly higher concentration of serum albumin (ca. 0.6 mM)
than a1-AGP (0.02 mM) most likely results in a noticeable
quenching of both the Tb and Eu excited states by charge
transfer from serum albumin.
To account for serum albumin quenching, a three-
dimensional titration chart was plotted by considering simul-
taneous variation of the concentration of both human serum
albumin and human a1-AGP. The resulting plot, (Fig. 12),
revealed the rising trend for the 5D4/
7F5/
5D0/
7F2 intensity
ratio at any given concentration of HSA, although the slope of
the plotted curve is in turn a function of the HSA concentration.
The dependence is shallower at higher concentrations of HSA,
consistent with more eﬃcient competitive binding of [EuL1]
and [TbL1] to HSA as its concentration rises. The described
system could be improved further by introducing a third
component, which has a diﬀerent spectral response to both
HSA and human a1-AGP compared to [EuL
1] and [TbL1], or one
that is non-responsive to the presence of each of the two
proteins. Such a system could then provide simultaneous
monitoring of the concentration of both proteins in serum,
allowing a calibration surface for variable concentrations of
HSA and human a1-AGP to be dened.
Competitive drug-binding studies
In contrast to serum albumin, only one well-dened binding
pocket is present in a1-AGP. This pocket can permit the trans-
port of essential drugs in plasma, and in several cases the drug
is preferentially bound to serum albumin. It has been shown
recently that a luminescent europium complex can be eﬃciently
used for determining binding constants of selected drugs to
human a1-AGP, by competitive replacement of the luminescent
complex bound to the protein with added drug, accompanied by
the changes in the total emission intensity and induced CPL
Fig. 11 Change of the total emission spectrumof [EuL1]/[TbL1] (22 mM/
2 mM) ‘cocktail’ upon addition of human a1-AGP to human serum (pH
¼ 7.40, lex ¼ 310 nm, 298 K).
Fig. 12 Variation of the relative intensity of emission bands at 515–
567 nm and 602–636 nm of the mixture of [EuL1] and [TbL1] (21 mM/
0.8 mM) as a function of added HSA and human a1-AGP (lex ¼ 310 nm,
298 K).
This journal is © The Royal Society of Chemistry 2018 Chem. Sci., 2018, 9, 2996–3003 | 3001
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signal.12 The determined binding constants were in good
agreement with previously reported values, corroborating the
applicability of this approach.
In the present study, three common drugs – imatinib, lido-
caine and bupivacaine (Fig. 13) – were used to examine
competitive binding between [EuL1] and bovine or human a1-
AGP (Table 3). Addition of lidocaine (Fig. S15†) and bupivacaine
(Fig. S17†) to human a1-AGP with bound [EuL
1] revealed binding
constants (log K ¼ 4.4 and 5.6 respectively) similar to those
previously reported (log K ¼ 4.4 and 5.7 respectively). A very
similar value was observed in analogous experiments with bovine
a1-AGP (log K ¼ 4.5) for lidocaine (Fig. S16†), although the value
for bupivacaine (Fig. S18†) was found to be signicantly higher
(log K ¼ 6.4). In each case, the total emission intensity of [EuL1]
returned to the initial value observed in the absence of added
protein, when an excess of the drug has been added.
A diﬀerent situation was observed when imatinib (Fig. S19
and S20†) was added to the proteins with bound [EuL1]. Addi-
tion of imatinib did not seem to completely displace bound
[EuL1], as the spectral signature of the europium complex and
the dissymmetry factor of the terbium analogue [TbL1] bound to
bovine a1-AGP did not change upon addition of the drug.
Emission quenching was observed for both europium and
terbium complexes, and the total emission intensity of [EuL1]
with excess of added drug was lower than for the complex
without added protein, suggesting an eﬃcient non-radiative
quenching of the biaryl chromophore by imatinib inside the
drug-binding pocket (e.g. by a p–p stacking interaction).
Signicantly lower binding constants were calculated for the
binding of imatinib to human a1-AGP (log K ¼ 5.6 vs. log K ¼
6.4), and this was even an order of magnitude lower (log K¼ 4.8)
in the case of bovine a1-AGP.
The relatively low binding constant of [EuL1] to human and
bovine a1-AGP permitted competitive binding experiments to be
carried out, e.g. with lidocaine and bupivacaine – drugs that
both posses higher binding aﬃnities towards a1-AGP than
[EuL1]. In spite of the diﬀerences between human and bovine
a1-AGP in their amino-acid content near the drug-binding site,
similar binding constants were found in each case. The terbium
analogue, [TbL1], with a strong induced CPL signal when bound
to bovine a1-AGP can itself be used for monitoring drug-
binding, by following the variation of the dissymmetry factor.
Conclusions
Water-soluble and pH-responsive macrocyclic lanthanide
complexes with a biaryl chromophore exhibit a high aﬃnity
towards the human and bovine forms of the serum protein, a1-
AGP. The emission of [EuL1] is quenched in aqueous solution in
the absence of the protein, and showed a 30-fold increase in
emission intensity upon adding a1-AGP. Furthermore, this pH-
responsive probe showed a strong CPL signal, which intrigu-
ingly showed opposite signs for the human and bovine variants
of a1-AGP. As the [EuL
1] and [TbL1] complexes showed diﬀerent
sensitivity towards added a1-AGP, their mixture could be used in
creating a ratiometric system to determine the concentration of
a1-AGP, in either human or bovine serum. Competitive binding
studies with popular prescription drugs showed little diﬀerence
in aﬃnity between human and bovine variants of a1-AGP.
Changes in the emission spectral signature of the europium
complex as a function of pH revealed the reversible switch
between a twisted square antiprismatic structure (TSAP) at
higher pH and a mono-capped square antiprismatic (SAP)
coordination at lower pH. The corresponding structures of the
Eu and Dy systems were simulated using a combined DFT and
NMR pseudocontact shi (PCS) tting analysis, estimating the
pseudocontact shis from the behaviour of the diamagnetic
analogue [YL1]. The simulation allowed the full magnetic
susceptibility tensor for [DyL1] to be calculated, and it was
found to be remarkably similar to that recently found for the
complex [DyL4] which also possesses an eight-coordinate TSAP
structure. Taken together, such NMR and computational anal-
yses are in agreement with the large change in solution struc-
ture revealed by emission analysis that allows the assessment of
the europium ligand eld parameters, B20 and B
2
2, whose sign
changes upon the TSAP and SAP interconversion. Indeed, in the
past, such behaviour has either been overlooked or mis-
apprehended,26 and yet it can explain the very dramatic changes
in paramagnetic NMR and lanthanide emission spectral
behaviour that can characterise both large21b and surprisingly,
even more subtle ligand eld perturbations.27
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Fig. 13 Molecular structures of drugs used in the present study.
Table 3 Binding aﬃnities of [EuL1], lidocaine, bupivacaine and imatinib
to bovine and human a1-AGP (pH ¼ 7.40, 298 K). Literature values are
given in parentheses;24,25 no literature data is available for the bovine
AGP drug aﬃnities
[EuL1] Lidocaine Bupivacaine Imatinib
Human a1-AGP 4.1 4.5 (4.4) 5.6 (5.7) 5.6 (6.4)
Bovine a1-AGP 4.7 4.5 6.4 4.8
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